A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
Phase 3
Active, not recruiting
NCT06095102
| Condition | Plaque Psoriasis |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Janssen Research & Development, LLC |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 311 participants |
|---|
| Interventions | JNJ-77242113 |
|---|
| Start date | Oct 12, 2023 |
|---|
| Completion date | Jun 19, 2024 |
|---|
| Results posted | Jun 25, 2026 |
|---|
Summary
The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16
Week 16 · Percentage of participants
| Arm 1: Placebo | 5.8 Percentage of participants |
|---|
| Arm 2: JNJ-77242113 200 mg | 56.7 Percentage of participants |
|---|
| p-value | <0.001 |
|---|
| Treatment difference | 51.1 (95% CI 42.1–58.8) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.